Abstract 3366
Background
The microbiota community is considered as an organ of the human body. Recent studies have found that dysbiosis may have an impact on the interaction between immune regulation and tumor treatment. The main objective of this study is to characterize the gut microbiota in patients with non-small cell lung cancer (NSCLC) in advanced stages, and its relationship with obesity, smoking habits, clinical pathological features and response to treatment with immune-checkpoints blockers (ICB).
Methods
16S rRNA gene sequencing was performed on 48 stool samples from advanced NSCLC patients prior to treatment with ICB (PD-1 inhibitor and PD-L1 inhibitor). The database used for the taxonomic assignation was the SILVA_release_132. The parametric statistical analysis was performed in SPSS package (15.0). A p-value <0.05 was considered statistically significant for all analyzes.
Results
The average age of the 48 patients was (64±10 years), of which 36 patients were male, 27 patients present PD-L1 positive, 28 patients with smoking habits. 261 different genus were detected in all the samples, being Bacteroides 28.11%, Alistipes 6.58% and Prevotella 4.67% the more frequently found. Non-smokers presented significantly higher richness and diversity (Chao1 p = 0.001, Shannon p = 0.001, Simpson p = 0.03) compared with current and former smokers. Greater abundance of genus Blautia was associated with obesity (p = 0.043). In addition, according to histology, greater abundance of genus Odoribacter was observed in squamous cell carcinoma patients compared to adenocarcinoma (p = 0.04); and regarding stage, stage IIIB patients presented higher proportion of genus Lactobacillus than stage IV (p = 0.017).Patients with progression disease to the ICB treatment presented significantly higher abundance of genus Ruminococcaceae_UCG-013 (p = 0.019).
Conclusions
We have been demonstrated a potential relationship between the gut microbiota in NSCLC patients and clinical-pathological features, which requires confirmation in a larger study. The more relationship with the ICB is under evaluation and will be presented at the meeting. Funded by CB16/12/00350 from CIBEROnc, PI18/00226, and PI15-00753 from ISCIII.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fundación Investigación Hospital General Universitario Valencia.
Funding
CIBEROnc, Instituto de Salud Carlos III.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract